Brief: Abbisko Cayman Says FY Loss Attributable RMB495.6 Mln
15/03/2023 11:33
March 15 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* FY LOSS ATTRIBUTABLE RMB495.6 MILLION VERSUS LOSS RMB1.81
BILLION
* DO NOT EXPECT PANDEMIC TO HAVE ANY MATERIAL IMPACT ON
OVERALL
CLINICAL DEVELOPMENT PLANS IN LONG TERM
Source text for Eikon: ID:nHKS4xRWt0
Further company coverage: 2256.HK
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly